Cosmo Pharmaceuticals Receives Complete Response Letter from the FDA on Methylene Blue MMX NDA
Cosmo Pharmaceuticals NV today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its submission of a New Drug Application (NDA) for Methylene Blue MMX, which is intended as a visualization aid to increase detection of lesions in the colon.